ImmunoGen, Inc. Appoints Anna Berkenblit, MD, MMSc Vice President and Chief Medical Officer
April 01 2015 - 8:00AM
Business Wire
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that
develops targeted anticancer therapies using its antibody-drug
conjugate (ADC) technology, today announced the appointment of Anna
Berkenblit, MD, MMSc, as Vice President and Chief Medical Officer.
Dr. Berkenblit reports to Dr. Charles Morris, EVP and Chief
Development Officer and is responsible for leading the clinical
development of ImmunoGen’s novel, wholly owned product candidates.
Dr. Berkenblit has extensive experience in the clinical development
of novel anticancer therapies, including five years heading
clinical research at two oncology-focused companies.
“We are very pleased to welcome Anna to the ImmunoGen team,”
commented Dr. Morris. “Anna brings an important depth of experience
in the clinical development of novel, targeted anticancer agents.
She has directed programs ranging from initial clinical testing to
registration-directed trials across a number of cancer types. Her
experience will be highly valuable as we prepare to advance our
product candidates into later stages of development.”
Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice
President, Clinical Development at H3 Biomedicine, a developer of
targeted anticancer compounds founded by Eisai Pharmaceuticals.
Prior to H3 Biomedicine, she was VP, Head of Clinical Research at
AVEO Oncology, where she led the clinical development of oncology
product candidates spanning early testing to registration trials.
Prior to AVEO, Dr. Berkenblit held positions of increasing
responsibility at Wyeth and then Pfizer, becoming Vice President,
Neratinib Asset Team Leader in the Pfizer Oncology Business
Unit.
Dr. Berkenblit earned an MD degree from Harvard Medical School,
and a MMSc degree in the Clinical Investigator Training Program of
Harvard/MIT Health Sciences & Technology. She did her
internship and residency at Brigham and Women’s Hospital and a
hematology/oncology fellowship at Beth Israel Deaconess Medical
Center, where she also ran the Phase I oncology clinical trial
program as part of the Dana-Farber/Harvard Cancer Center.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells. The
Company utilizes its ADC technology with its antibodies to create
ImmunoGen product candidates and also out-licenses limited rights
to use its technology to other companies. Roche’s Kadcyla® is the
first marketed product with ImmunoGen’s ADC technology. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024